Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Niagen Bioscience (NAGE) approved a share repurchase program authorizing up to $10.0 million of common stock. Purchases may occur in open market or privately negotiated transactions, or under a trading plan adopted in the future, in accordance with applicable securities laws.
The authorization expires on October 31, 2027 and can be modified, suspended, or terminated at any time at the Board’s discretion. The program does not obligate the company to buy any specific amount of shares.
Niagen Bioscience, Inc. furnished an 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025, and posted a corporate presentation on its website.
The press release is included as Exhibit 99.1 and the presentation as Exhibit 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed “filed” under the Exchange Act.
Niagen Bioscience (NAGE) reported strong Q3 2025 results. Net sales were $33,986 thousand, up from $25,580 thousand a year ago. Operating income rose to $4,236 thousand and net income reached $4,578 thousand, or $0.05 diluted earnings per share. Cash and cash equivalents were $64,290 thousand as of September 30, 2025.
For the nine months, net sales were $95,584 thousand with net income of $13,250 thousand. Operating cash flow was $12,825 thousand, reflecting improved profitability and working capital. Segment mix in Q3 showed Consumer Products at $26,017 thousand and Ingredients at $7,197 thousand. As of November 3, 2025, there were 79,806,139 common shares issued and outstanding.
The company received $2,650,000 from the Elysium California settlement. In a separate Delaware matter, a final judgment awarded $9.2 million in fees and costs plus interest; the company has appealed and disclosed a reasonably possible loss of approximately $10.4 million. Trade receivables totaled $8,506 thousand, with 64.9% concentrated among three customers, and major-customer sales in the quarter included Life Extension at 11.9% and A.S. Watson Group at 10.8%.
Niagen Bioscience, Inc. disclosed in a Current Report on Form 8-K that on October 6, 2025 it issued a press release announcing an increase to its financial outlook for the full year ending December 31, 2025. The company states the press release is furnished as Exhibit 99.1 and clarifies this information is being furnished, not filed, under the Exchange Act so it is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated. No specific revenue, earnings, or guidance figures are included in the filing text provided.
Niagen Bioscience is registering an additional 4,750,000 shares of its common stock (par value $0.001) for issuance under the 2017 Equity Incentive Plan following a stockholder-approved increase to the plan's share reserve on June 24, 2025. The filing incorporates prior S-8 registrations and references the company's recent annual and quarterly SEC reports for the disclosures that govern these awards. These shares will be available for issuance as employee and director equity awards under the amended plan.
Niagen Bioscience, Inc. has filed a Form S-8 to register 650,000 shares of its common stock for issuance under its Employee Stock Purchase Plan, enabling eligible employees and subsidiaries to acquire company shares through that plan. The Registration Statement incorporates the company’s recent annual, quarterly and current reports and refers to its previously filed description of common stock so investors can find detailed financial and disclosure history by reference.
The filing describes standard Delaware-law indemnification protections for directors and officers, the company’s authority to purchase insurance for such persons, and confirms key corporate governance documents and the ESPP are attached as exhibits. The statement is procedural and does not present standalone financial results or new material transactions that change the company’s financial condition.
Niagen Bioscience (Nasdaq:NAGE) filed a Form 8-K detailing the outcomes of its 24 June 2025 Annual Meeting.
- 2017 Equity Incentive Plan: share reserve increased by 4,750,000 shares.
- New ESPP: 650,000 shares available; purchase price set at 85% of the lower of the offering- or purchase-date close.
- All eight directors re-elected; Crowe LLP ratified as auditor.
- Advisory say-on-pay passed (54,899,483 for / 1,160,619 against).
The amended plan (Ex. 10.1) and ESPP (Ex. 10.2) were filed; no other material changes were disclosed.